TIANRONG MEDICAL GROUP, INC

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020

PREPARED BY MANAGEMENT

UNAUDITED

Table of Contents

TIANRONG MEDICAL GROUP, INC
BALANCE SHEETS
(Unaudited)

	December 31, 2021	December 31, 2020
ASSETS		Proforma
Current assets		
Cash	$ 63,620	$ 68,552
Accounts receivable	5,094,562	7,121,232
Prepaid	---	1,975,747
Total current assets	5,158,182	9,165,531
Property and equipment- net	2,234	184,857
Intangible assets	704,050	683,899
Right to use lease	2,105,367	
Development costs	327,613	1,465
Investments	39,491	242,425
Total assets	$ 8,336,937	$ 10,278,176
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current liabilities:		
Accounts payable and accrued expense	$ 506,860	$ 669,072
Other payables	864,448	3,686,290
Notes payable – related parties	902,652	--
Notes payable	142,961	503,013
Operating lease	164,424	----
Total current liabilities	2,579,345	4,858,375
Operating lease long term	484,938	--
Total liabilities	3,155,768	4,858,375
Stockholders' deficit:		
Preferred shares, $0.001 par value 500,000 authorized,500,000 and zero issued and outstanding, respectively	5	--
Common stock, $0.01 par value, 1,000,000,000 authorized, 500,000,000 and 35,916,969 issued and outstanding, respectively	500,000	35,917
Additional paid in capital	5,503,502	5,746,043
Comprehensive currency	--	--
Accumulated deficit	(730,853)	(362,169)
Total stockholders' deficit	5,272,654	5,419,801
Total liabilities and stockholder deficit	$ 8,336,937	$ 10,278,176

The accompanying notes are an integral part of these unaudited financial statements.

TIANRONG MEDICAL GROUP, INC
STATEMENTS OF OPERATIONS
AS OF DECEMBER 31,
(Unaudited)

	Year Ended	
	2021	2020
Revenue	$ 646,145	--
Cost of sales	(176,123)	--
Gross margin	470,022	--
Operating expenses:		
General and administrative expense	749,830	--
Income (loss) from operations	(279,808)	--
Other income(expense)		
Other income	1,268	--
Interest expense	(90,144)	--
Total other income (expense)	(88,876)	--
Net loss	(368,684)	$ -
Net loss per share, basic and diluted	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding, basic and diluted	484,916,969	35,916,969

The accompanying notes are an integral part of these unaudited financial statements.

TIANRONG MEDICAL GROUP, INC
CHANGES IN STOCKHOLDER EQUITY

	Preferred Stock		Common Stock		Additional Paid-In	Stockholders'	
	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2019	--	--	35,916,969	$ 35,917	$ 5,746,043	$ (362,169)	$ 5,419,801
Net loss	--		--	--	--	--	--
Balance at December 31, 2020	--	--	35,916,966	35,917	5,746,043	(362,169)	5,419,801
Common stock issued for acquisition			449,000,000	449,000	(267,536)	--	181,464
Preferred shares issued for service	500,000	5	--	--	24,995	--	25,000
Common stock issued for service	--	--	15,083,031	15,083	--	--	15,083
Net loss	--	--	--	--	--	(368,684)	(368,684)
Balance at September 30, 2021	500,000	$5	500,000,000	$500,000	$ 5,503,502	$ (730,853)	$ 5,272,654

The accompanying notes are an integral part of these unaudited financial statements.

TIANRONG MEDICAL GROUP, INC
STATEMENTS OF CASH FLOWS
AS OF DECEMBER 31,

	2021	2020
Cash flows from operating activities:		
Net loss	$ (368,684)	$ --
Adjustments to reconcile net income to net cash		
Used in operating activities:		
Depreciation	7,285	--
Stock for service	40,083	--
Right to use lease	(2,105,367)	--
Changes in operating assets and liabilities:		
Deposits	1,975,747	--
Accounts Receivable	2,026,670	--
Operating lease	647,362	--
Accounts payable and accrued expenses	(2,424,318)	--
Net cash provided by (used in) operating activities	(201,222)	--
Cash flows used in investing activities		
Purchase of fixed assets	--	--
Net cash used in investing activities	--	--
Cash flows from financing activities		
Notes payable – related parties	902,652	--
Payment of convertible notes	(360,045)	--
Effect of Intangible assets	(346,300)	--
Net cash provided by financing activities	196,290	--
Effect of foreign currency on cash	--	--
Net increase (decrease) in cash	(4,9329)	--
Cash – beginning of year	68,552	--
Cash – end of year	$ 63,620	$ --
SUPPLEMENT DISCLOSURES:		
Interest paid	$ --	$ --
Income taxes paid	$ --	$ --

TIANRONG MEDICAL GROUP, INC
NOTES TO FINANCIAL STATEMENTS
(Unaudited)

NOTE 1 - DESCRIPTION AND HISTORY OF BUSINESS AND HISTORY

Tianrong Medical Group, Inc. (the "Company"), was incorporated on February 7, 2000 under the laws of the State of Nevada, to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisition. On March 10, 2020, a change of domicile was filed with the Colorado Secretary of State and is currently in good standing with the state of Colorado.

On December 28, 2020,the Company signed a definitive agreement to acquire Huan Media Company Limited, parent company of China based Sichuan Huan Media Co. Ltd., in an all-stock transaction.

On February 1, 2021, the Company issued 449,000,000 shares of common stock for the acquisition of Huan Media Company Limited.

Huan Media owns exclusive operation rights and provides free Wi-Fi services and entertainment platforms to several railway lines and in over hundreds of railway stations and trains across China. Huan Media is growing at a rapid pace, aiming at providing services to over 1 billion of annual railway passenger flow in 2021. Huan Media guarantees fully secured, uninterrupted service, even when the external 3G and 4G signals are weak or unavailable. Its unmatched platforms provide unique and exclusive services to passengers, including online ticketing, train schedule information, VIP services, onboard online shopping, travel, and hotel bookings. It also provides passengers with rich entertainment content; recent movies, hit music and mobile games. This exclusive platform is an effective advertisement and product promotion channel for location centric products to globally recognized brands. Huan Media was established in 2013. As China's number one railway transportation Wi-Fi operator and a leader in China's rail transportation information service, it focuses on the construction and operation of mobile internet in the field of public transportation, internet product development and distribution, big data analysis and scene-based precision marketing services. The company is headquartered in Chengdu, Sichuan Province, China.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of Tianrong Medical Group, Inc is presented to assist in understanding the Company's financial statements. The financial statements and notes are representations of the Company's management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative deficit of ($730,853) since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Basis of Presentation – The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. All references to Generally Accepted Accounting Principles ("GAAP") are in accordance with The FASB Accounting Standards Codification ("ASC") and the Hierarchy of Generally Accepted Accounting Principles.

Use of estimates – The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires the use of estimates and assumptions regarding certain types of assets, liabilities, revenues, and expenses. Such estimates primarily relate to unsettled transactions and events as of the date of the financial statements. Accordingly, upon settlement, actual results may differ from estimated amounts.

Cash and cash equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents.

Fair Value of Financial Instruments – The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items. The Company does not hold any investments that are available-for-sale.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity)

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, "*Income Taxes*", which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 "*Compensation-Stock Compensation*", which provides investors and other users of financial statements with more complete and neutral financial information, by requiring that the compensation cost relating to share-based payment transactions be recognized in the financial statements. That cost will be measured based on the fair value of the equity or liability instruments issued. ASC 718-10 covers a wide range of share-based compensation arrangements, including share options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As of December 31, 2021, the Company issued 15,083,031 shares of common stock with a value of $15,083 for service.

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") 260-10 "*Earnings Per Share*", which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net loss per share gives effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.

Recent Accounting Pronouncements – The Company has evaluated all recent accounting pronouncements through ASU 2017-07, and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.

NOTE 3 –NOTES PAYABLE

The Company has $142,961 in short term notes due on demand plus $902,652 in notes payable related parties which are due on demand.

NOTE 4 – EQUITY

Preferred shares

The Company as authorized 50,000,000 shares of preferred stock with a par value of $0.00001. Each shares has 4,000 votes to one vote for each common share.

During the year ended December, 31, 2021, the Company issued 500,000 shares of preferred stock with a value of $25,000 for service.

Common stock

The Company has 1,000,000,000 shares of common stock authorized with a par value of $0.001 per share,

During the year ended December 31, 2021, the Company issued 449,000,000 shares of common stock for the acquisition of Huan Media..

During the year ended December 31, 2021, the Company issued 15,083,031 shares of common stock for service with a value of $15,083.

NOTE 5 – SUBSEQUENT EVENTS

The Company has evaluated events subsequent events of the financial statements from Dece3mber 31, 2021 through April 12, 2022 and has determined that there are no such events that would require adjustment to, or disclosure in, the financial statements.